MapLight Q4 net loss $79.5M; cash $453M; Phase 2 readouts expected Q3 2026

MapLight Therapeutics, Inc.

Net loss of $79.5M in Q4 2025 vs $21.2M year ago; FY2025 loss $161.2M vs $77.6M.
Cash, equivalents and investments $453.1M as of Dec 31, 2025, expected to fund operations through 2027.
Phase 2 ZEPHYR trial for schizophrenia: target enrollment (n=300) expected April 2026; topline results Q3 2026.
Phase 2 IRIS trial for autism spectrum disorder completed enrollment; topline results expected Q3 2026.
FDA Fast Track granted for ML-007C-MA in Alzheimer's disease psychosis; VISTA trial topline H2 2027.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

MapLight Therapeutics, Inc. reported the fourth quarter of 2025 results: net income $79.5 million.

Period: the fourth quarter of 2025
Net income: $79.5 million
Result: reported results

Exact text from the filing

Net loss was $79.5 million for the fourth quarter of 2025, as compared to $21.2 million for the prior year period.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

MapLight Therapeutics, Inc. reported the full year 2025 results: net income $161.2 million.

Period: the full year 2025
Net income: $161.2 million
Result: reported results

Exact text from the filing

For the full year 2025, net loss was $161.2 million, as compared to $77.6 million for the full year 2024.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

MapLight Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-125062

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.